These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15138159)

  • 1. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
    Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
    Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
    Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
    Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
    Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
    Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Wasik-Szczepanek E; Bojarska-Junak A; Rolinski J; Döhner H; Stilgenbauer S; Bullinger L
    Leukemia; 2009 Oct; 23(10):1771-8. PubMed ID: 19440214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
    Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
    Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
    Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
    Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
    Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
    Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
    Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
    Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
    Morales AA; Olsson A; Celsing F; Osterborg A; Jondal M; Osorio LM
    Int J Cancer; 2005 Feb; 113(5):730-7. PubMed ID: 15499630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
    Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
    Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
    Grgurevic S; Montilla-Perez P; Bradbury A; Gilhodes J; Queille S; Pelofy S; Bancaud A; Filleron T; Ysebaert L; Récher C; Laurent G; Fournié JJ; Cazaux C; Quillet-Mary A; Hoffmann JS
    Haematologica; 2018 Jun; 103(6):1038-1046. PubMed ID: 29567785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
    López-Guerra M; Trigueros-Motos L; Molina-Arcas M; Villamor N; Casado FJ; Montserrat E; Campo E; Colomer D; Pastor-Anglada M
    Haematologica; 2008 Dec; 93(12):1843-51. PubMed ID: 18945750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.
    Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB
    Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.